Triple negative breast cancer (TNBC) has historically been one of the most aggressive and difficult-to-treat forms of breast cancer. Unlike other breast cancer types, TNBC does not have estrogen, progesterone, or HER2 receptors — which means many common targeted therapies are not effective.
However, treatment options have expanded significantly in recent years.
According to research supported by the National Institutes of Health (NIH) and the National Cancer Institute (NCI), three newer therapeutic agents — alongside conventional chemotherapy — are now considered among the most important treatment approaches for triple negative breast cancer: pembrolizumab (Keytruda), sacituzumab govitecan (Trodelvy), and olaparib (Lynparza).
These advances represent major progress toward more personalized and effective care.
1. Pembrolizumab (Keytruda) — Immunotherapy
Pembrolizumab is an immune checkpoint inhibitor that works by helping the body’s immune system recognize and attack cancer cells.
It is approved for:
- High-risk early-stage triple negative breast cancer (in combination with chemotherapy)
- Metastatic TNBC in certain patients
According to a 2025 publication in the National Library of Medicine, pembrolizumab combined with chemotherapy has demonstrated improved outcomes in both early and advanced triple negative breast cancer settings.
Source:
National Library of Medicine (NIH), 2025
https://pmc.ncbi.nlm.nih.gov/articles/PMC11974553/
2. Sacituzumab Govitecan (Trodelvy) — Antibody-Drug Conjugate
Sacituzumab govitecan is part of a newer class of treatments known as antibody-drug conjugates (ADCs). These therapies deliver chemotherapy directly to cancer cells by targeting specific proteins — in this case, the Trop-2 protein commonly found on triple negative breast cancer cells.
It is most often used in metastatic TNBC, particularly after other treatments have been tried.
According to a 2024 NIH-supported review, sacituzumab govitecan has shown meaningful clinical benefit in patients with advanced triple negative breast cancer, improving progression-free survival compared to standard chemotherapy.
Source:
National Library of Medicine (NIH), 2024
https://pmc.ncbi.nlm.nih.gov/articles/PMC12629933/
3. Olaparib (Lynparza) — PARP Inhibitor
Olaparib is a targeted therapy called a PARP inhibitor. It is specifically used for patients who have inherited BRCA1 or BRCA2 gene mutations and HER2-negative breast cancer, including triple negative breast cancer.
PARP inhibitors work by preventing cancer cells from repairing damaged DNA, which ultimately causes the cancer cells to die.
According to the National Cancer Institute, PARP inhibitors such as olaparib are an important treatment option for patients with BRCA-mutated breast cancers in both early-stage and metastatic settings.
Source:
National Cancer Institute (NIH), Updated 2023
https://www.cancer.gov/about-cancer/treatment/drugs/olaparib
Why This Matters for Patients
For many years, chemotherapy was the primary treatment option for triple negative breast cancer.
Today, patients may have access to:
- Immunotherapy
- Targeted antibody-drug therapies
- Genetic-based precision medicine
- Combination treatments that improve outcomes
These developments are giving patients more options and more hope than ever before.
Important Reminder
Not every treatment is right for every patient. Treatment decisions depend on:
- Cancer stage
- Genetic testing results (such as BRCA mutations)
- Biomarker status (such as PD-L1)
- Overall health
- Previous treatments
Patients should always discuss options with their oncology care team.
At Byrd Cancer Foundation, we believe education empowers patients and families to advocate for themselves and make informed decisions.
If you or someone you love is navigating triple negative breast cancer, know that advances in treatment continue to evolve — and you are not alone.
